NEWPORT NEWS, Virginia (October 13, 2014) – The Minnesota Department of Human Services (Minnesota Medicaid) now provides coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds. This compliments a decision previously taken by Medicare to cover TheraSkin in Minnesota.

“We applaud the decision by the Minnesota Medicaid Program to cover this limb and life-saving product for their more than 700,000 Medicaid recipients,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Minnesota residents with diabetic and venous leg ulcers will now have access to clinically and cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these types of ulcers.

Patients who will particularly benefit from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

About 16% of adults in Minnesota over 65 have been diagnosed with diabetes, twice the percentage in 1994. “We will work tirelessly with the medical institutions and practitioners in Minnesota to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing.

Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.

For more information on Minnesota coverage, please go to http://www.dhs.state.mn.us/main/idcplg?IdcService=GET_DYNAMIC_CONVERSION&RevisionSelectionMethod=LatestReleased&dDocName=id_010122. TheraSkin code on the fee schedule is Q4121.